Cdk inhibitors in development and cancer

被引：2
|
作者：
Harper, JW
Elledge, SJ
机构：
[1] BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030
[2] BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030
来源：
CURRENT OPINION IN GENETICS & DEVELOPMENT | 1996年 / 6卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Activation of cyclin-dependent kinases is the primary control point of cell proliferation. Recent advances in the understanding of cell-cycle regulation have uncovered two families of proteins that bind and inhibit these kinases. These proteins are likely mediators of development and differentiation, and may provide molecular connections between the pathways of development and tumorigenesis.
引用
下载
收藏
页码：56 / 64
页数：9
相关论文
共 50 条
  • [21] Nanoformulations of PARP and CDK inhibitors for cancer therapy
    Singh, Bijay
    Yang, Shicheng
    Baldwin, Paige
    van de Ven, Anne
    Sridhar, Srinivas
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [22] Recent advances in CDK inhibitors for cancer therapy
    Heptinstall, Amy B.
    Adiyasa, I. W. S.
    Cano, Celine
    Hardcastle, Ian R.
    FUTURE MEDICINAL CHEMISTRY, 2018, 10 (11) : 1369 - 1388
  • [23] Development and strategies of CDK4/6 inhibitors
    Chen, Pingping
    Xu, Yinqiu
    Li, Xuanyi
    Yao, Hequan
    Lin, Kejiang
    FUTURE MEDICINAL CHEMISTRY, 2020, 12 (02) : 127 - 145
  • [24] Development of mice without Cip/Kip CDK inhibitors
    Tateishi, Yuki
    Matsumoto, Akinobu
    Kanie, Tomoharu
    Hara, Eiji
    Nakayama, Keiko
    Nakayama, Keiichi I.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 427 (02) : 285 - 292
  • [25] Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures
    Cheng, Weiyan
    Yang, Zhiheng
    Wang, Suhua
    Li, Ying
    Wei, Han
    Tian, Xin
    Kan, Quancheng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 164 : 615 - 639
  • [26] CDK4/6 inhibitors in breast cancer
    Dukelow, Tim
    Kishan, Divya
    Khasraw, Mustafa
    Murphy, Conleth G.
    ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
  • [27] Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer
    Goel, Bharat
    Tripathi, Nancy
    Bhardwaj, Nivedita
    Jain, Shreyans K.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (17) : 1535 - 1563
  • [28] Perspectives for cancer therapies with cdk2 inhibitors
    Wadler, S
    DRUG RESISTANCE UPDATES, 2001, 4 (06) : 347 - 367
  • [29] Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors
    Dwyer, Michael P.
    Paruch, Kamil
    Alvarez, Carmen
    Doll, Ronald J.
    Keertikar, Kerry
    Duca, Jose
    Fischmann, Thierry O.
    Hruza, Alan
    Madison, Vincent
    Lees, Emma
    Parry, David
    Seghezzi, Wolfgang
    Sgambellone, Nicole
    Shanahan, Frances
    Wiswell, Derek
    Guzi, Timothy J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (22) : 6216 - 6219
  • [30] IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER
    Petroni, Giulia
    Gouin, Kenneth
    Martinez, Aitziber Buque
    Knott, Simon
    Formenti, Silvia
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A763 - A763
12345